ArticlePakistan journal of medical sciences2025
Effect of interferon combined with ganciclovir on immune status in children with infectious mononucleosis.
Article in Pakistan journal of medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical characteristics in hospitalized children with infectious mononucleosis in Shanghai China: a single-center retrospective study.Italian journal of pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the effect of interferon combined with ganciclovir on immune status in children with infectious mononucleosis(IM) and explore the clinical efficacy. Methodology: This was a retrospectively study. A total of 90 children with IM admitted to Baoding Hospital, Beijing Children's Hospital Affiliated to Capital Medical University from January 2022 to December 2023 were divided into the observation and control groups using a random number table. Afterward, the pre- and post-treatment humoral immunity indicators (IgG, IgA) and cellular immunity indicators (CD3+, CD4+, CD4+/CD8+) were compared between the observation and control groups. Results: IgG, IgA, CD3+, CD4+, and CD4+/CD8+ values in the observation group were significantly changed compared with those in the control group pre- and post-treatment, with statistical significance (p< 0.05); the post-treatment IgG, IgA, CD4+, and CD4+/CD8+ values in the two groups were significantly higher than the pre-treatment values, and CD3+ values were markedly lower than pre-treatment values, with statistical significance(p< 0.05); the post-treatment IgA and CD3+ values in the observation group were higher and lower than those in the control group, respectively, with statistical significance(p< 0.05). Conclusion: Human interferon α-1b combined with ganciclovir in the treatment of IM leads to faster subsidence of clinical manifestation. Meanwhile, IgA and CD3+ are sensitive experimental indicators with certain clinical significance in evaluating the effect of IM, which can be used as a reference for evaluating the efficacy of drugs and disease outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.